Immune Response News and Research

RSS

Scientists discover role of OTUD7B enzyme as TRAF3's protector

Marked for death with molecular tags that act like a homing signal for a cell's protein-destroying machinery, a pivotal enzyme is rescued by another molecule that sweeps the telltale targets off in the nick of time.

21 Jan 2013

Scientists identify new mechanism that turns CD4 helper T lymphocytes into killer cells

A research team led by the La Jolla Institute for Allergy & Immunology has discovered the mechanism that enables CD4 helper T cells to assume the more aggressive role of killer T cells in mounting an immune attack against viruses, cancerous tumors and other damaged or infected cells.

21 Jan 2013

Mature CD4+ helper T lymphocytes can be re-programed to gain killing functions

The fate of mature T lymphocytes might be a lot more flexible than previously thought. New research from the RIKEN Center for Allergy and Immunology (RCAI) in Japan and La Jolla Institute for Allergy and Immunology (LIAI) in the USA shows for the first time that mature CD4+ helper T lymphocytes can be re-programed to become killer-like CD8+ T lymphocytes and gain killing functions.

21 Jan 2013

New study: Loneliness can harm overall health

New research links loneliness to a number of dysfunctional immune responses, suggesting that being lonely has the potential to harm overall health.

20 Jan 2013

Flu virus can essentially tell time: Research

Scientists have discovered that that the flu virus can essentially tell time, thereby giving scientists the ability to reset the virus' clock and combat it in more effective ways. According to researchers at the Icahn School of Medicine at Mount Sinai, the flu knows how much time it has to multiply, infect other cells, and spread to another human being. If it leaves a cell too soon, the virus is too weak. If it leaves too late, the immune system has time to kill the virus.

18 Jan 2013

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Miscarriage and molecular signals: an interview with Prof Brosens and Prof Quenby

Miscarriage is defined as the spontaneous loss of pregnancy before the baby reaches viability. Besides the physical trauma, miscarriage causes considerable anxiety, stress, and depression.

17 Jan 2013

New menu of 61 genetically engineered E. coli strains may improve efficacy of vaccines

Researchers at The University of Texas at Austin have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

17 Jan 2013

Researchers discover molecular blueprint behind the IFIT protein

Researchers at McGill University and the Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences have discovered the molecular blueprint behind the IFIT protein.

15 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Sublingual immunotherapy can effectively treat peanut allergy

Peanuts are one of the most common triggers of severe food-induced allergic reactions, which can be fatal, and the prevalence of peanut allergy is increasing. However, there is currently no clinical treatment available for peanut allergy other than strict dietary elimination and, in cases of accidental ingestion, injections of epinephrine.

9 Jan 2013

Vaccine gives HIV patients a long-term boost

A functional cure for HIV-1 seems feasible after research shows that an immunotherapeutic vaccine demonstrated long-term efficacy at reducing viral load when administered to patients in the early stages of disease.

7 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Researchers identify four new genetic regions associated with Behcet's disease

Researchers have identified four new regions on the human genome associated with Behcet's disease, a painful and potentially dangerous condition found predominantly in people with ancestors along the Silk Road.

7 Jan 2013

Immune response more complicated than thought

Researchers have found that the orientation and concentration of antibodies could determine the control of bacterial infection.

28 Dec 2012

Uncharacterized TLR plays key role in Toxoplasma gondii response

A previously uncharacterized toll-like receptor appears to play a crucial role in the innate immune response to Toxoplasma gondii infection and may promote host resistance, potentially leading to anti-parasite vaccines, say US researchers.

28 Dec 2012

Immune-promoting drugs may control recurrent disease

Nearly half of the 700,000 cancer patients who undergo surgical removal of a primary tumor each year suffer a recurrence of their disease at some point, and many of those patients will eventually die from their disease.

28 Dec 2012

Genome sequencing may help identify new targets to treat Pneumocystis pneumonia

Scientists have sequenced the genome of the fungus Pneumocystis jirovecii, an advancement that could help identify new targets for drugs to treat and prevent Pneumocystis pneumonia, a common and often deadly infection in immunocompromised patients.

26 Dec 2012

Blood transfusion may increase risk of death in heart attack patients with anemia

When heart attack patients present in the emergency department with some degree of anemia, or anemic patients have a heart attack, physicians have a tendency, but not much guidance, about whether to provide a blood transfusion.

25 Dec 2012